{"title":"波利多卡诺在经皮硬化剂注射治疗动脉瘤性骨囊肿中的作用 - 一项单中心研究","authors":"PAVAN KUMAR BABU, S. S, AJAY RAIDU G, UMA SHANKAR","doi":"10.22159/ajpcr.2024v17i7.50704","DOIUrl":null,"url":null,"abstract":"Objectives: To study the clinical and radiological outcomes in patients treated with 3% polidocanol as a sclerosing agent in percutaneous sclerotherapy for aneurysmal bone cyst (ABC).\nMethods: This is a single-centered retrospective study conducted in the Department of Orthopaedics at Kurnool Medical College with 23 patients from 2018 to 2021 over 3 years, where 3% polidocanol was used as a sclerosing agent in percutaneous sclerotherapy as a treatment option for ABC. Postoperatively, patients are evaluated based on clinical and radiological examinations.\nResults: Clinically, patients were compared to their own Visual Analog Score (VAS) at the time of healing to the VAS score during their first visit. The mean VAS during the first visit was 7.6. At the time of healing, there were only two patients who scored a score of 1 on the VAS. Radiologically, plain radiographs were observed for ossification. 20 (86.9%) patients achieved complete ossification, 2 (8.69%) patients could achieve partial ossification.\nConclusion: With this study, we would like to present that percutaneous sclerotherapy with 3% polidocanol is effective both clinically and radiologically in the treatment of ABCs. Our institution has adopted sclerotherapy as part of salvage therapy and as the first line of treatment in treating ABC tumors.","PeriodicalId":8528,"journal":{"name":"Asian Journal of Pharmaceutical and Clinical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ROLE OF POLIDOCANOL IN PERCUTANEOUS SCLEROTHERAPY IN TREATMENT OF ANEURYSMAL BONE CYST – A SINGLE-CENTER STUDY\",\"authors\":\"PAVAN KUMAR BABU, S. S, AJAY RAIDU G, UMA SHANKAR\",\"doi\":\"10.22159/ajpcr.2024v17i7.50704\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: To study the clinical and radiological outcomes in patients treated with 3% polidocanol as a sclerosing agent in percutaneous sclerotherapy for aneurysmal bone cyst (ABC).\\nMethods: This is a single-centered retrospective study conducted in the Department of Orthopaedics at Kurnool Medical College with 23 patients from 2018 to 2021 over 3 years, where 3% polidocanol was used as a sclerosing agent in percutaneous sclerotherapy as a treatment option for ABC. Postoperatively, patients are evaluated based on clinical and radiological examinations.\\nResults: Clinically, patients were compared to their own Visual Analog Score (VAS) at the time of healing to the VAS score during their first visit. The mean VAS during the first visit was 7.6. At the time of healing, there were only two patients who scored a score of 1 on the VAS. Radiologically, plain radiographs were observed for ossification. 20 (86.9%) patients achieved complete ossification, 2 (8.69%) patients could achieve partial ossification.\\nConclusion: With this study, we would like to present that percutaneous sclerotherapy with 3% polidocanol is effective both clinically and radiologically in the treatment of ABCs. Our institution has adopted sclerotherapy as part of salvage therapy and as the first line of treatment in treating ABC tumors.\",\"PeriodicalId\":8528,\"journal\":{\"name\":\"Asian Journal of Pharmaceutical and Clinical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Journal of Pharmaceutical and Clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22159/ajpcr.2024v17i7.50704\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22159/ajpcr.2024v17i7.50704","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的研究在动脉瘤性骨囊肿(ABC)经皮硬化剂治疗中使用 3% polidocanol 作为硬化剂的患者的临床和放射学结果:这是一项单中心回顾性研究,库尔诺尔医学院骨科从2018年至2021年的3年间共收治了23名患者,在经皮硬化剂注射治疗动脉瘤骨囊肿的过程中使用了3%波利多卡诺作为硬化剂。术后,根据临床和放射学检查对患者进行评估:在临床上,将患者痊愈时的视觉模拟评分(VAS)与首次就诊时的 VAS 评分进行比较。首次就诊时的平均 VAS 为 7.6。在痊愈时,只有两名患者的 VAS 得分为 1 分。放射学方面,平片观察骨化情况。20名患者(86.9%)实现了完全骨化,2名患者(8.69%)实现了部分骨化:通过这项研究,我们认为使用 3% 玻利多孔菌醇进行经皮硬化剂注射在临床和影像学上都能有效治疗 ABC。我院已将硬化剂注射疗法作为挽救疗法的一部分,并作为治疗ABC肿瘤的一线疗法。
ROLE OF POLIDOCANOL IN PERCUTANEOUS SCLEROTHERAPY IN TREATMENT OF ANEURYSMAL BONE CYST – A SINGLE-CENTER STUDY
Objectives: To study the clinical and radiological outcomes in patients treated with 3% polidocanol as a sclerosing agent in percutaneous sclerotherapy for aneurysmal bone cyst (ABC).
Methods: This is a single-centered retrospective study conducted in the Department of Orthopaedics at Kurnool Medical College with 23 patients from 2018 to 2021 over 3 years, where 3% polidocanol was used as a sclerosing agent in percutaneous sclerotherapy as a treatment option for ABC. Postoperatively, patients are evaluated based on clinical and radiological examinations.
Results: Clinically, patients were compared to their own Visual Analog Score (VAS) at the time of healing to the VAS score during their first visit. The mean VAS during the first visit was 7.6. At the time of healing, there were only two patients who scored a score of 1 on the VAS. Radiologically, plain radiographs were observed for ossification. 20 (86.9%) patients achieved complete ossification, 2 (8.69%) patients could achieve partial ossification.
Conclusion: With this study, we would like to present that percutaneous sclerotherapy with 3% polidocanol is effective both clinically and radiologically in the treatment of ABCs. Our institution has adopted sclerotherapy as part of salvage therapy and as the first line of treatment in treating ABC tumors.